Accéder au contenu
Merck

Effects of olanzapine and paroxetine on phospholipase D activity in the rat brain.

Pharmacological reports : PR (2013-08-21)
Marek Krzystanek, Ewa Krzystanek, Henryk I Trzeciak, Andrzej Małecki, Irena Krupka-Matuszczyk, Małgorzata Janas-Kozik, Janusz K Rybakowski
RÉSUMÉ

Phospholipase D (PLD) plays a key role in a second messenger system producing phosphatidic acid, mediating, among others, serotonin 5-HT2 receptor activity. The aim of the study was to evaluate a possible effect of atypical antipsychotic drug, olanzapine (OLZ), and selective serotonin reuptake inhibitor (SSRI) antidepressant, paroxetine (PX), on oleate-activated PLD activity in plasma membranes isolated from rat brain cortex. PLD activity was determined using a fluorometric assay. Ritanserin was used to determine the 5-HT receptor mode of action. A single dose of 10 mmol/kg OLZ produced no change in rat brain cortex PLD activity, 20 mmol/kg OLZ caused a nonsignificant decrease, and long-term (21 days) administration of OLZ resulted in a 41.9% decrease in PLD activity. Single doses of PX significantly decreased PLD activity: 10 mmol/kg - by 28.6%; 20 mmol/kg - by 31.5%, and long-term (21 days) administration of PX - by 39.5%. The study indicates that the 5-HT2 receptor-mediated inhibition of oleate-activated PLD may be a common part of the mechanisms of action of OLZ and PX.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Paroxetine hydrochloride (anhydrous), European Pharmacopoeia (EP) Reference Standard
Référence
Conditionnement
Disponibilité
Prix
Quantité